CRISPR therapy cuts hereditary angioedema by 81% in Phase 2 study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and...
View ArticleFacing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots
LAS VEGAS — MGM Resorts plans to stop covering GLP-1 weight loss shots for its employees next year, after it faced constraints in what it could do to manage soaring costs without losing crucial drug...
View ArticleBayer, Dewpoint to work on heart drug; Viking’s obesity manufacturing plans
Plus, news about Interius BioTherapeutics, Hope Medicine, PMV Pharmaceuticals, Epitopea, Alyssum Therapeutics and a new dementia trial accelerator in the UK: Bayer exercises option to develop heart...
View ArticleZai Lab unveils early lung cancer data as it looks to challenge Amgen's...
Zai Lab released Phase 1a data Thursday morning as it attempts to compete with a recently approved Amgen drug. The program, known as ZL-1310, induced a 74% response rate among 19 patients with...
View ArticleClik here to view.
Marinus plans another round of layoffs, cost cuts following Phase 3 fail
Marinus Pharmaceuticals is reducing its workforce again and taking other measures to reduce costs after its epilepsy treatment failed a late-stage trial. The TrustTSC trial investigating oral...
View ArticleRoche returns to Dyno for its AAV tech with $50M upfront
Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting neurological diseases, expanding the scope of an existing partnership that started...
View ArticleLonza extends contract with unnamed pharma; Rentschler's new build
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza said it has extended a contract to produce monoclonal...
View ArticleClik here to view.
Icon's quarterly earnings hit by biotech and pharma pullback
Cost and research cuts across biotech and pharma are affecting some of the contracting companies that rely on the industry. Steve Cutler The latest victim is Icon, a Dublin-based contract research...
View ArticleBridgeBio shares promising results in trial of Canavan disease gene therapy
BridgeBio disclosed results Thursday from a Phase 1/2 study of its gene therapy for Canavan disease, an extremely rare and devastating genetic disorder that causes the brain’s white matter to break...
View ArticleCDC advisors decline to recommend RSV shots to younger at-risk adults,...
The CDC’s vaccine policy advisors haven’t budged on new RSV guidance, remaining unconvinced that younger adults at higher risk of disease should get the shot. That was the takeaway from a presentation...
View ArticleSanofi backs fibrosis biotech Agomab as it raises $89M Series D
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said Friday that the French drug giant and Invus are new investors in its $89 million...
View ArticleClik here to view.
Sanofi reports sales jump for Beyfortus as RSV antibody challenger from Merck...
As Sanofi declares strong early sales for Beyfortus in its second RSV season, the French pharma is confident that it would still come out on top against potential competitor Merck because its antibody...
View ArticleGSK to spend $800M to build two vaccine factories in the US
GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania. Two new facilities will double the current size...
View ArticleClik here to view.
Chinook alums reunite following exit to Novartis; The first board appointment...
Tom Frohlich → Tom Frohlich has signed on as CEO of autoimmune disease specialist Jade Biosciences, a company in the Paragon portfolio that raised an $80 million launch round in August. Frohlich...
View ArticleSepterna bags $288M upsized IPO for GPCR drugs
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday. Investors seemed enthused by the prospects of the GPCR biotech. They...
View ArticleClik here to view.
Elucida Oncology shutters due to 'lack of funding'
Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has learned. The New Jersey startup was trying to take a different approach in the...
View ArticleEnGene’s $60M PIPE; AbbVie to develop neuropsychiatric drugs with Gedeon Richter
Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences: EnGene snags $60M: The Boston and Montreal gene therapy biotech raised the private placement from new and current...
View ArticleBristol Myers, Ideaya report new data for solid tumors with MTAP deletion
Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting solid tumors with a certain mutation known as MTAP deletion. There are no...
View ArticleClik here to view.
Lyell Immunopharma to acquire ImmPACT Bio, cut top programs
Lyell Immunopharma is discontinuing several programs and acquiring CAR-T biotech ImmPACT Bio and its suite of clinical-stage candidates for $30 million in upfront cash and 37.5 million shares of...
View ArticleClik here to view.
Tyra Biosciences gives a first look at its challenge to J&J’s targeted...
Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first presentation of human data since its inception in...
View Article